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Aims: To assess patient-reported outcomes (PROs) in patients with overactive bladder (OAB) receiving the novel
b3-adrenoceptor agonistmirabegron.Methods: Data from a randomised, double-blind, controlled phase III trial in 1,987
patients aged18 years with OAB symptoms for 3 months were analysed. Patients received placebo, mirabegron 50 or
100mg/day, or tolterodine extended release (ER) 4mg orally once daily for 12 weeks after a 2-week placebo run-in.
Prespecified analysis of PROs (changes in OABQuestionnaire [OAB-q], Patient Perception of Bladder Condition [PPBC],
and Work Productivity and Activity Impairment: Specific Health Problem [WPAI-SHP] instrument) in patients treated
with mirabegron 50mg/day, tolterodine ER 4mg/day or placebo is reported. Post-hoc analyses of OAB-q, PPBC and the
Treatment Satisfaction-Visual Analogue Scale (TS-VAS) in patients who were incontinent at baseline are also reported.
Results: Significant improvements over placebo in OAB-q coping and concern from baseline to final visit were observed
with mirabegron 50mg/day. No significant improvements in these parameters were observed with tolterodine ER 4mg/
day.Mirabegron 50mg/day significantly increased the proportion of patients showing a PPBC improvement over placebo.
Mirabegron 50mg/day also produced greater improvements in WPAI-SHP presenteeism and greater reductions in
absenteeism and overall work impairment than placebo or tolterodine ER 4mg/day. The impact of mirabegron 50mg/day
treatment on PROs in the incontinent population appears to be greater than that in the overall OAB population.
Conclusions: At the approved dose of 50mg/day,mirabegron significantly improvesOABpatients’ perception of disease
and quality of life, independent of whether they are incontinent at baseline. Neurourol. Urodynam.
# 2015 The Authors. Neurourology and Urodynamics published by Wiley Periodicals, Inc.
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INTRODUCTION
Overactive bladder (OAB) is a chronic condition characterised
by urinary urgency, usually accompanied by frequency and
nocturia, with or without urgency urinary incontinence.1 OAB
can significantly interfere with daily routines and health-
related quality of life (HRQoL), including social, physical and
psychological well-being, productivity and sexual health, and
can cause stress and depression.2
The efficacy ofOAB treatment has traditionally been assessed
using bladder diaries during confirmatory clinical trials (phase
III). These diaries, usually completed by patients for 3–7 days,
are reliable and appropriate for capturing objective endpoints,
such as micturition frequency and number of incontinence
episodes, but are not designed to capture patient quality of life
or perception of treatment benefit. The use of validated patient-
reported outcomes (PROs) in addition to bladder diaries allows
both objective and subjective endpoints to be captured, and can
therefore provide information regarding treatment perfor-
mance of use for regulatory decisions and clinical decision
making. Subjective endpoints are particularly important when
assessing treatments associated with bothersome side effects,
because these can affect persistence and adherence.3,4 Further-
more, subjective endpoints can provide information on
whether treatments meet patient expectations, which influ-
ence the impact of OAB on HRQoL.3
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Antimuscarinic drugs are often the primary pharmacological
treatment for OAB symptoms, but may not meet treatment
expectations and/or may be associated with troublesome side
effects such as dry mouth, constipation, cognitive alterations,
particularly in the elderly, and blurred vision.4,5 Mirabegron, a
b3-adrenergic agonist approved for the treatment of OAB, has a
mechanism of action that is distinct from antimuscarinic
agents.6 A pivotal phase III trial (SCORPIO; NCT00689104), in
which 1,987 patients with OAB were randomised to placebo,
mirabegron 50 or 100mg/day or tolterodine extended release
(ER) 4mg/day, included as an active control, showed statistically
significant reductions in numbers of incontinence episodes and
micturitions per 24hrwithmirabegron 50 and 100mg/day over
placebo.7 Note that the design of the trial did not allow direct
comparisons between mirabegron 50 or 100mg/day and
tolterodine ER 4mg/day. Although the overall incidence of
treatment-emergent adverse events was similar with placebo,
mirabegron 50 or 100mg/day and tolterodine ER 4mg, the
incidence of drymouthwith tolterodine ER 4mg/daywas 10.1%
andwithmirabegron50mg/daywas 2.8%.7 Based on these data,
mirabegron 50mg/day is approved for the treatment of OAB.
It is reasonable to expect improvements in the balance
between drug efficacy and tolerability to translate into
improved HRQoL. Mirabegron at a dose of 50 and 100mg/day
significantly improved outcomes for three PROs, Treatment
Satisfaction-Visual Analogue Scale (TS-VAS), Symptom Bother
on the OAB Questionnaire (OAB-q), and Patient Perception of
Bladder Condition (PPBC), compared to placebo in the pivotal
phase III SCORPIO trial.7 Data for other PROs defined as
secondary endpoints in this trial for mirabegron 50mg/day,
tolterodine ER 4mg and placebo are reported here, together
with the results of a post-hoc PRO analysis in the subgroup of
patients with incontinence at baseline.
MATERIALS AND METHODS
Study Design
SCORPIO was a multicentre, randomised, double-blind,
parallel-group, placebo- and active-controlled phase III trial,
full details of which have been reported previously.7 Briefly,
patients aged18 years with symptoms of OAB for3months
entered a 2-week, single-blind, placebo run-in to determine
baseline symptoms, during which they were required to have
an average micturition frequency of 8 per 24hr and 3
episodes of urgency, with or without incontinence, during a 3-
day micturition diary period. Those meeting enrolment criteria
were randomised to oral placebo, mirabegron 50mg or 100mg/
day, or tolterodine ER 4mg once daily for 12 weeks (Appendix
Figure S1). Clinic visits were scheduled at baseline andweeks 4,
8 and 12/end of treatment (final visit). The primary comparison
was between mirabegron and placebo, with a secondary
comparison between tolterodine ER 4mg/day and placebo.7
No direct comparisons between mirabegron and tolterodine
were made.
The study was approved by institutional review boards and
was conducted in accordance with the ethical principles of the
Declaration of Helsinki, Good Clinical Practice, International
Conference on Harmonisation guidelines, and all applicable
laws and regulations. All patients provided written informed
consent.
PRO Assessments
TS-VAS. As previously reported, the change in treatment
satisfaction from baseline to final visit was assessed using the
TS-VAS, with which a higher score indicates greater treatment
satisfaction.7 Data are reported only for the subgroup of
patients who were incontinent at baseline.
OAB-q. The OAB-q is a robust and validated disease-specific
instrument for OAB with 33 items, the first eight of which are
for the symptom severity score, with higher scores equating to
worse bother.8 Total HRQoL is expressed as the sum of four
subscales (items 9–33) that include coping, concern, sleep and
social aspects; higher scores indicate better HRQoL. The OAB-q
was assessed at baseline and weeks 4, 8 and 12/end of
treatment, and subscale and total scores were transferred onto
a scale of 0–100. The change in symptom bother score has been
reported elsewhere7; here, we present data on coping, concern,
sleep and social aspects for mirabegron 50mg/day, tolterodine
ER 4mg/day and placebo.
PPBC. The PPBC is a validated global single-item OAB tool
with concurrent and discriminate validity that assesses
responses on a six-point categorical Likert scale, with higher
scores equating to bladder condition that causes greater
problems.9 It was administered at baseline and week 12/end
of treatment, and changes from baseline have been reported
previously.7 We present here a responder analysis for patients
treated with mirabegron 50mg/day, tolterodine ER 4mg/day
or placebo showing improvement (1 point) and major
improvement (2 points).
Work productivity and activity impairment: specific health
problem (WPAI-SHP) instrument. TheWPAI-SHP instrumentwas
used to assess the effect of therapy on work productivity. This
tool is a widely used work productivity instrument, with
established reliability and validity.10 The tool usedwas adapted
from the specific health problem version of theWPAI to address
OAB; absenteeism (time missed at work), presenteeism
(impairment while at work), overall work impairment (combi-
nation of absenteeism and presenteeism) and activity im-
pairment were assessed. Higher scores for each of these
parameters indicate greater impairment and less productivity.
Incontinence pad use. Incontinence pad usewasmonitored to
evaluate the effect of therapy on OAB-related medical care
resources. The population for this analysis consisted of patients
treated with mirabegron 50mg/day, tolterodine ER 4mg/day
or placebo who reported using at least one pad in the
micturition diary completed over a 3-day period at baseline.
Subgroup Analysis
A post-hoc analysis of changes in PPBC, OAB-q scores and TS-
VAS with mirabegron 50mg/day, tolterodine ER 4mg/day and
placebo was performed in the subgroup of patients who were
incontinent at baseline.
Statistical Analyses
The full analysis set (FAS: all patients randomised to
mirabegron 50mg/day, tolterodine ER 4mg/day or placebo
who received at least one dose of study medication and had a
baseline and at least one post-baseline micturition measure-
ment) was used for the prespecified analysis of the secondary
endpoints. The subgroup analysis was based on the FAS-
incontinence (FAS-I) population of patients who had at least
one incontinence episode in the baseline diary. Patient progress
and analysis sets have been described previously.7
Missing items from OAB-q were handled using the half-scale
rule: a score was calculated when 50% of items were missing
from a subscale, but was set to ’missing’ if >50% of items were
not available. If any subscale score was unavailable, the HRQoL
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total score was set to ‘‘missing’’. Missing values were not
imputed for any other QoL-related questionnaire.
Change from baseline to final visit for each endpoint was
analysed using an analysis of covariance (ANCOVA) including
treatment, sex and geographical region as fixed factors and
baseline as a covariate. Based on the ANCOVA, least squares
mean estimates and two-sided 95% confidence intervals (CIs)
for mean changes from baseline were derived within
treatment groups and between the mirabegron 50mg/day
treatment group and placebo. Responder endpoints were
summarised using number and percentage of subjects. Two-
sided 95% CIs for the differences in the percentage of
responders between active treatment and placebo are based
on normal approximation. Odds ratios, corresponding two-
sided 95% CIs and P values were derived from a logistic
regression model including treatment group, sex, geographi-
cal region and baseline value.
RESULTS
Study Population
A total of 1,987 patients were randomised. Of these, 1,428
patients were included in the FAS population for this analysis
(placebo 480; mirabegron 50mg/day 473; tolterodine ER 4mg/
day 475); baseline characteristics were comparable across
treatment groups (Table I).
OAB-q
Significant improvements compared to placebo in coping,
concern and HRQoL total score were observed for mirabegron
50mg/day (Table II). No statistically significant improvements
in these scores were observed for tolterodine ER 4mg/day vs.
placebo.
PPBC Responder Analysis
In the PPBC responder analysis, statistically significantly
more patients improved (1 point improvement relative to
placebo) with both mirabegron 50mg/day and tolterodine ER
4mg/day, but no statistically significant major improvements
(2 points relative to placebo) were observed (Table II).
WPAI-SHP
Reductions in scores for all parameters assessed using the
WPAI-SHPwere observed, reflecting reductions in absenteeism,
overall work impairment and activity impairment and an
improvement in presenteeism. Mirabegron 50mg/day pro-
duced numerically greater reductions in absenteeism and
overall work impairment than placebo or tolterodine ER 4mg/
day (Table III), as well as improving presenteeism more than
placebo or tolterodine ER 4mg/day. The reduction in activity
impairment was similar with mirabegron 50mg/day and with
tolterodine ER 4mg/day, both ofwhich had numerically greater
effects than placebo.
Incontinence Pad Use
Reductions in pad use compared to placebo were observed
with both active therapies at 4weeks, butwere not statistically
significant (Fig. 1). Further reductions in pad use were observed
with mirabegron 50mg/day between weeks 4 and 12, but
differences relative to placebowere not statistically significant.
Subgroup Analysis of Patients Who Were Incontinent at Baseline
(FAS-I Population)
A total of 884 of 1,428 patients (61.9% of those in the
FAS population for this analysis) were incontinent at baseline:
291/480 (60.6%), 293/473 (62.0%) and 300/475 (63.2%) of
patients in the placebo, mirabegron 50mg/day and tolterodine
ER 4mg/day arms, respectively. Baseline characteristics were
generally comparable across the treatment groups, although
the incontinent population differed from the FAS in that there
weremorewomen and duration of symptomswas longer in the
FAS-I population (Table I). As expected the proportion of
patients with urgency incontinence OAB and mixed stress/
urgency incontinence OABwas also higher in the FAS-I than the
FAS population.
Data for the PROs assessed in the FAS-I population are shown
in Table IV. In general, absolute changes in PROs from baseline
were greater in the FAS-I population than in the FAS population
with both placebo andmirabegron 50mg/day or tolterodine ER
4mg/day. For the OAB-q, changes from baseline in symptom
bother were significantly greater with mirabegron 50mg/day
and tolterodine ER 4mg/day than with placebo, and numeri-
cally greater withmirabegron 50mg/day thanwith tolterodine
ER 4mg/day (Table IV). Mirabegron 50mg/day produced
statistically significant improvements in coping and concern
scores compared to placebo, but the changewith tolterodine ER
4mg/day was not statistically significant. Mirabegron 50mg/
day showed improvements compared to placebo in sleep and
social scores that were not statistically significant. For
tolterodine ER 4mg/day, changes from baseline for the sleep
and social scores were similar to placebo. Mirabegron 50mg/
day statistically significantly improved OAB-q total HRQoL,
whereas the improvement with tolterodine ER 4mg/day was
limited and not statistically significant (Table IV). Numerical
improvement in PPBC over placebo was seen with both
mirabegron 50mg/day and tolterodine ER 4mg/day, with
statistical significance achieved for tolterodine ER 4mg/day.
Treatment satisfaction as assessed using the TS-VAS was
statistically significantly greater with mirabegron 50mg/day
and tolterodine ER 4mg/day than placebo. Mirabegron 50mg/
day showed numerically greater improvements than tolter-
odine ER 4mg/day (Table IV).
Overall, compared to placebo, the impact of active treatment
on PROs in the FAS-I population appears to be greater than that
in the FAS population.
DISCUSSION
Patient perception of the efficacy and tolerability of OAB
therapy is the most important determinant of patient adher-
ence and persistence.3 PROs are therefore necessary when
assessing both new and existing agents for the treatment of
OAB. Furthermore, because individual patients differ in their
perception of what constitutes treatment success or failure,
measures of treatment response must account for patient
characteristics, and PROs provide information demonstrating
the importance of observed symptom changes to patients’
lives.11 The reported analysis showed that 12 weeks of therapy
with mirabegron at the approved dose of 50mg/day produces
significant improvements in OAB-q components and PPBC
compared to placebo. Such improvements compared to placebo
were not observed with tolterodine ER 4mg/day. Furthermore,
mirabegron treatment was associated with numerical im-
provements in WPAI-SHP scores and with at least numerical
reductions in incontinence pad use at 4 weeks. With regard to
differences in WPAI-SHP scores, it is not possible to assess
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whether these are clinically meaningful because minimal
clinically important differences do not appear to have been
established. Furthermore, it should be noted that pad use may
be linked to factors such as reassurance, because pads are often
worn even when a patient has become continent, as well as a
high placebo response, a lack of drug effect, or other types
of incontinence, which may explain the lack of significant
difference at 12 weeks.
Changes in these PROs compared to placebo were generally
greater withmirabegron 50mg/day therapy in the incontinent
patient population than those in the overall study population.
These greater changes were observed despite treatment with
placebo also appearing to have a greater effect in the
incontinent patient population than in the overall study
population. These observations suggest that patients with
incontinence perceive the benefit of mirabegron therapy as
being even greater than those who do not have incontinence.
These findings support the efficacy of mirabegron 50mg/day
in terms of urgency, urinary incontinence and urinary
frequency reported earlier for this trial,8 and are in agreement
with the results of PRO analyses reported as secondary
endpoints in this and other phase III studies.12,13 They also
support pooled analyses of phase III trials ofmirabegron, which
have reported significant improvements in TS-VAS over
TABLE II. OAB-q and PPBC Outcomes for the FAS Population
Treatment group
Parameter
Placebo
(n¼ 480)
Mirabegron
50mg/day (n¼ 473)
Tolterodine ER
4mg/day (n¼475)
Change from baseline to final visit in OAB-q coping score
Patients available (n¼ 474) (n¼ 468) (n¼ 470)
Adjusted mean change from baseline (SE) 15.5 (0.93) 18.5 (0.93) 17.8 (0.93)
Mean difference vs. placebo (SE) NA 2.9 (1.31) 2.3 (1.31)
95% two-sided CI NA 0.4, 5.5 0.3, 4.8
P-value NA 0.025 0.083
Change from baseline to final visit in OAB-q concern score
Patients available (n¼ 474) (n¼ 469) (n¼ 470)
Adjusted mean change from baseline (SE) 15.7 (0.86) 18.4 (0.87) 16.2 (0.87)
Mean difference vs. placebo (SE) NA 2.6 (1.22) 0.4 (1.22)
95% two-sided CI NA 0.2, 5.0 2.0, 2.8
P-value NA 0.033 0.74
Change from baseline to final visit in OAB-q sleep score
Patients available (n¼ 475) (n¼ 469) (n¼ 470)
Adjusted mean change from baseline (SE) 13.2 (0.86) 15.1 (0.87) 13.9 (0.87)
Mean difference vs. placebo (SE) NA 1.9 (1.23) 0.7 (1.23)
95% two-sided CI NA 0.5, 4.3 1.7, 3.1
P-value NA 0.12 0.56
Change from baseline to final visit in OAB-q social score
Patients available (n¼ 475) (n¼ 469) (n¼ 470)
Adjusted mean change from baseline (SE) 8.7 (0.68) 10.1 (0.68) 8.8 (0.68)
Mean difference vs. placebo (SE) NA 1.4 (0.96) 0.1 (0.96)
95% two-sided CI NA 0.5, 3.3 1.7, 2.0
P-value NA 0.15 0.88
Change from baseline to final visit in OAB-q HRQoL
total score
Patients available (n¼ 473) (n¼ 468) (n¼ 470)
Adjusted mean change from baseline (SE) 13.7 (0.76) 16.1 (0.77) 14.8 (0.77)
Mean difference vs. placebo (SE) NA 2.3 (1.08) 1.1 (1.08)
95% two-sided CI NA 0.2, 4.5 1.1, 3.2
P-value NA 0.031 0.32
Patients with 1-point improvement in PPBC
(baseline to final visit)
Patients available (n¼ 433) (n¼ 416) (n¼ 426)
Percentage of patients 56.6 61.3 65.0
Difference vs. placebo (%) NA 4.7 8.4
Odds ratio vs. placebo NA 1.36 1.43
95% CI NA 1.02, 1.82 1.07, 1.91
P-value NA 0.036 0.015
Patients with 2-point improvement in PPBC
(baseline to final visit)
Patients available (n¼ 433) (n¼ 416) (n¼ 426)
Percentage of patients 28.2 29.1 31.5
Difference vs. placebo (%) NA 0.9 3.3
Odds ratio vs. placebo NA 1.15 1.16
95% CI NA 0.84, 1.56 0.85, 1.56
P-value NA 0.38 0.35
ER, extended release; FAS, full analysis set; HRQoL, health-related quality of life; NA, not applicable; OAB-q, Overactive Bladder Questionnaire; PPBC, Patient
Perception of Bladder Condition; SE, standard error.
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12 weeks for mirabegron 50mg/day versus placebo14 and
significant changes from baseline for EuroQol five dimensions
questionnaire (EQ-5D) utilities for mirabegron 50mg/day
versus tolterodine ER 4mg/day.15
Satisfaction with treatment is influenced by many factors in
addition to the objective measures commonly assessed in
clinical trials, such as symptom improvement. Patient expect-
ations of treatment efficacy and adverse events are important
in determining whether they continue on their OAB medica-
tion.3 Against this background, interest in patient perception of
treatment has increased. The Food and Drug Administration
has established the PRO Consortium to develop, evaluate, and
qualify PRO instruments16 and has issued guidance on the use
of PROs to support regulatory submissions.17 Similarly,
the European Medicines Agency has published guidance on
the use of HRQoL in clinical trials generally and in patientswith
urinary incontinence specifically.18,19 However, consensus on
the best approach to PRO assessment is currently lacking.
Therefore, this study used a variety of tools, includingmeasures
of symptom bother, several HRQoL tools and an instrument to
assess the impact of the patient’s condition on work activity.
The effects observed with mirabegron 50mg/day with these
different tools were generally positive and indicated improve-
ments in disease perception and quality of life, and reduced
impact of disease on activity, all of which are considered
relevant for people with OAB. The improvements in TS-VAS
with mirabegron 50mg/day were proportionally greater than
might have been expected from the PPBC data, particularly for
PPBC improvement and major improvement results, whereas
changes for these endpoints versus placebo were proportional-
ly more similar for tolterodine ER 4mg/day. This might reflect
differences in the efficacy/tolerability balance of the different
agents, which the TS-VAS would be more likely to identify in
view of its focus on satisfaction with treatment as opposed to
the disease itself.
As with similar OAB studies, the present study is subject to a
number of limitations, including the 12-week timeframe. On
this basis, it is difficult to estimate the likely longer-term effects
of mirabegron on PROs. The study was also not powered for a
head-to-head comparison of mirabegron and tolterodine,
which was included only as an active control. A study powered
to compare PROs with these agents would have provided
further insight into their relative benefits, which would have
been of particular interest given the inconsistent findings in
previous reports of the HRQoL benefit of different antimuscar-
inic agents.20,21 In addition, as in the primary efficacy analysis,7
a high placebo effect was observed, which may have obscured
treatment effects. Despite these limitations, these PRO findings
suggest meaningful benefit with mirabegron 50mg/day in
patients with OAB, particularly when considered in the context
of the previously reported positive clinical and HRQoL results.7
TABLE III. WPAI-SHP (Work Productivity and Activity Impairment: Specific Health Problem) Endpoints for the FAS Population
Treatment group
Parameter
Placebo
(n¼ 480)
Mirabegron
50mg/day (n¼ 473)
Tolterodine ER
4mg/day (n¼ 475)
Change from baseline to final visit in absenteeism
Patients available (n¼ 113) (n¼ 122) (n¼ 114)
Work time missed (absenteeism), % 0.2 1.8 1.2
Change from baseline to final visit in presenteeism
Patients available (n¼ 118) (n¼ 130) (n¼ 115)
Impairment while working (presenteeism), % 8.1 12.8 6.6
Change from baseline to final visit in overall work impairment
Patients available (n¼ 106) (n¼ 119) (n¼ 105)
Overall work impairment (absenteeismþpresenteeism), % 7.7 13.6 5.8
Change from baseline to final visit in activity impairment
Patients available (n¼ 419) (n¼ 400) (n¼ 409)
Activity impairment (general), % 11.0 14.9 14.3
ER, extended release; FAS, full analysis set.
Includes only patients who had baseline and post-baseline values. Data for absenteeism, presenteeism and overall work impairment were provided only by
people who were currently employed, whereas activity impairment data were provided regardless of employment status. No statistical analysis was carried
out for these endpoints; analysis is descriptive only.
Fig. 1. Mean change from baseline in mean number of incontinence pads
used per 24hr in the FAS. P<0.05 for active treatment vs placebo. ER,
extended release; FAS, full analysis set.
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CONCLUSIONS
Patients with OAB express significant dissatisfaction with
existing treatments, and especially antimuscarinic drugs.22 The
results of this phase III study indicate that at the approved dose
of 50mg/day the b3-adrenergic agonist mirabegron is clinically
effective7 and significantly improves patient-reported percep-
tions of their condition and quality of life, whether or not they
are incontinent at baseline. Incontinent patients, who have a
lower quality of life than the ‘dry’ OAB population,23 are
expected to obtain even greater benefit from mirabegron
therapy.
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